DNLI logo

Denali Therapeutics (DNLI)

Profile

Full Name

Denali Therapeutics Inc.

Ticker Symbol

DNLI

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

December 8, 2017

Indexes

Not included

Website

http://www.denalitherapeutics.com

Employees

422

Key Details

Price

$12.74(+1.51%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$2.57(-142.45% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$12.74
DNLI price is $12.74

30-Day Relative Volume

0.62
DNLI 30-day relative volume is 0.62

Price Performance

Price Most recent change

+1.51%
DNLI price was up +1.51% on Apr 17, 2025

Price YTD change

-37.49%
DNLI price is down -37.49% since January 1st

Price 1-year change

-24.26%
DNLI price is down -24.26% year-on-year

Price 3-year change

-57.69%
DNLI price is down -57.69% over the past 3 years

Price Range

Price All-time high

$93.94
DNLI price is currently -86.44% below its historical high of $93.94

Price 3-year low

$10.57
DNLI price is currently +20.53% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$1.85B
DNLI market capitalization is $1.85 billion

Market cap 3-year change

-50%
DNLI market capitalization is down -50% over the past 3 years

Market cap All-time high

$11.22B
DNLI market capitalization is currently -83.51% below its historical high of $11.22 billion

Market cap sector rank

82.88%
DNLI market capitalization is higher than 82.88% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.88%
DNLI shares outstanding is up +1.88% year-on-year

Shares Outstanding 3-Year Change

+18.16%
DNLI shares outstanding is up +18.16% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.44
DNLI beta is 1.44

200-day SMA

$22.58
DNLI price is currently -43.58% below its 200-day simple moving average

50-day SMA

$16.18
DNLI price is currently -21.25% below its 50-day simple moving average

RSI

42.15
DNLI 14-day relative strength index is 42.15

Volume

0.62
DNLI 30-day relative volume is 0.62

ATR

$1.02
DNLI average true range is $1.02

10-day Historical Volatility

86.69%
DNLI 10-day historical volatility is 86.69%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
DNLI annual revenue value is unknown

Revenue Analysts estimate

$28.37M
DNLI annual revenue is currently equal to the consensus analysts' forecast

Revenue 1-year change

-
DNLI annual revenue 1-year change is unknown

Revenue Sector rank

-
DNLI annual revenue is unknown

EPS

EPS

-$2.57
DNLI annual earnings per share is -$2.57

EPS Analysts estimate

-$2.87
DNLI annual earnings per share is currently -10.54% lower than the consensus analysts' forecast

EPS 1-year change

-142.45%
DNLI annual earnings per share is down -142.45% year-on-year

EPS Sector rank

33.31%
DNLI annual earnings per share is higher than 33.31% of companies in Healthcare sector

Profit

Gross profit

-
DNLI annual gross profit value is unknown

Gross margin

-
DNLI annual gross profit margin value is unknown

Operating profit

-$501.88M
DNLI annual operating income is -$501.88 million

Operating margin

-
DNLI annual operating profit margin value is unknown

Net income

-$422.77M
DNLI annual net profit is -$422.77 million

Net margin

-
DNLI annual net profit margin value is unknown

Expenses

Total expenses

$501.88M
DNLI annual total expenses is $501.88 million

Operating expenses

$501.88M
DNLI annual total operating expenses is $501.88 million

Cost of goods sold

-
DNLI annual cost of goods sold value is unknown

Selling, general & administrative expenses

$105.44M
DNLI annual SGA is $105.44 million

Depreciation and amortization

$8.99M
DNLI annual depreciation & amortization is $8.99 million

Interest expense

-
DNLI annual interest expense value is unknown

Income tax

$68.00K
DNLI annual income tax is $68.00 thousand

EBIT & EBITDA

EBIT

-$501.88M
DNLI annual earnings before interest & taxes is -$501.88 million

EBITDA

-$492.89M
DNLI annual EBITDA is -$492.89 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$1.37B
DNLI annual total assets is $1.37 billion

Non current assets

$509.74M
DNLI annual long term assets is $509.74 million

Current assets

$864.44M
DNLI annual total current assets is $864.44 million

Cash and cash equivalents

$174.96M
DNLI annual cash & cash equivalents is $174.96 million

Accounts receivable

$2.17M
DNLI annual accounts receivable is $2.17 million

Inventory

-
DNLI annual inventory value is unknown

Liabilities

Total liabilities

$144.50M
DNLI annual total liabilities is $144.50 million

Long term liabilities

$42.29M
DNLI annual total long term liabilities is $42.29 million

Current liabilities

$102.21M
DNLI annual total current liabilities is $102.21 million

Accounts payable

$11.14M
DNLI annual accounts payable is $11.14 million

Debt

Total debt

$48.71M
DNLI annual total debt is $48.71 million

Total debt 1-year change

-6.76%
DNLI annual total debt is down -6.76% year-on-year

Long term debt

$36.67M
DNLI annual long term debt is $36.67 million

Short term debt

$12.03M
DNLI annual short term debt is $12.03 million

Equity & Capital

Shareholders equity

$1.23B
DNLI annual stockholders equity is $1.23 billion

Book value

$1.23B
DNLI annual book value is $1.23 billion

Retained earnings

-$1.54B
DNLI annual retained earnings is -$1.54 billion

Working capital

$762.23M
DNLI annual working capital is $762.23 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$347.69M
DNLI annual cash flow from operations is -$347.69 million

Cash from operations 1-year change

+2.88%
DNLI annual cash flow from operations is up +2.88% year-on-year

Cash from investing

-$88.76M
DNLI annual cash flow from investing activities is -$88.76 million

Cash from investing 1-year change

-135.6%
DNLI annual cash flow from investing activities is down -135.6% year-on-year

Cash from financing

$484.30M
DNLI annual cash flow from financing activities is $484.30 million

Cash from financing 1-year change

+2617.76%
DNLI annual cash flow from financing activities is up +2617.76% year-on-year

CAPEX

CAPEX

-
DNLI annual capital expenditures value is unknown

CAPEX 1-year change

-
DNLI annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$363.61M
DNLI annual free cash flow is -$363.61 million

Free cash flow 1-year change

+1.97%
DNLI annual free cash flow is up +1.97% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
DNLI annual gross profit margin value is unknown

Operating margin

-
DNLI annual operating profit margin value is unknown

Net margin

-
DNLI annual net profit margin value is unknown

ROA & ROE

ROA

-30.77%
DNLI annual return on assets is -30.77%

ROE

-34.38%
DNLI annual return on equity is -34.38%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
DNLI price to earnings ratio value is unknown

PE ratio Sector rank

-
DNLI price to earnings ratio is unknown

PB Ratio

PB ratio

1.50
DNLI price to book ratio is 1.50

PB ratio Sector rank

55.98%
DNLI price to book ratio is higher than 55.98% of companies in Healthcare sector

PS Ratio

PS ratio

-
DNLI price to sales ratio value is unknown

PS ratio Sector rank

-
DNLI price to sales ratio is unknown

Enterprise value

Enterprise value

$1.72B
DNLI enterprise value is $1.72 billion

Enterprise value Sector rank

80.99%
DNLI enterprise value is higher than 80.99% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-3.50
DNLI EV/EBITDA is -3.50

EV/EBITDA Sector rank

23.85%
DNLI EV/EBITDA is higher than 23.85% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

8.46
DNLI annual current ratio is 8.46

Quick ratio

-
DNLI annual quick ratio value is unknown

Leverage

Debt to equity

0.04
DNLI annual debt to equity ratio is 0.04

Interest coverage ratio

-
DNLI annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
DNLI piotroski f-score value is unknown

Altman Z-Score

-
DNLI altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 10, 25 B of A Securities
Buy
Mar 5, 25 B. Riley Securities
Buy
Mar 3, 25 Oppenheimer
Outperform
Feb 28, 25 HC Wainwright & Co.
Buy
Feb 11, 25 Deutsche Bank
Buy
Jan 28, 25 Goldman Sachs
Buy
Jan 7, 25 JP Morgan
Overweight
Jan 7, 25 HC Wainwright & Co.
Buy
Jan 7, 25 Baird
Outperform
Jan 3, 25 William Blair
Outperform

Institutional Ownership

Similar stocks

ADUS logo
Addus HomeCare (ADUS)
CLOV logo
Clover Health Investments (CLOV)
PGNY logo
Progyny (PGNY)
Belite Bio (BLTE)
ENOV logo
Enovis (ENOV)
SDGR logo
Schrödinger (SDGR)
BHC logo
Bausch Health Companies (BHC)
TARS logo
Tarsus Pharmaceuticals (TARS)
NAMS logo
NewAmsterdam Pharma Company NV (NAMS)
  • What is the ticker symbol for Denali Therapeutics?
  • Does Denali Therapeutics pay dividends?
  • What sector is Denali Therapeutics in?
  • What industry is Denali Therapeutics in?
  • What country is Denali Therapeutics based in?
  • When did Denali Therapeutics go public?
  • Is Denali Therapeutics in the S&P 500?
  • Is Denali Therapeutics in the NASDAQ 100?
  • Is Denali Therapeutics in the Dow Jones?
  • When was Denali Therapeutics's last earnings report?
  • When does Denali Therapeutics report earnings?
  • Should I buy Denali Therapeutics stock now?

What is the ticker symbol for Denali Therapeutics?

The ticker symbol for Denali Therapeutics is NASDAQ:DNLI

Does Denali Therapeutics pay dividends?

No, Denali Therapeutics does not pay dividends

What sector is Denali Therapeutics in?

Denali Therapeutics is in the Healthcare sector

What industry is Denali Therapeutics in?

Denali Therapeutics is in the Biotechnology industry

What country is Denali Therapeutics based in?

Denali Therapeutics is headquartered in United States

When did Denali Therapeutics go public?

Denali Therapeutics's initial public offering (IPO) was on December 8, 2017

Is Denali Therapeutics in the S&P 500?

No, Denali Therapeutics is not included in the S&P 500 index

Is Denali Therapeutics in the NASDAQ 100?

No, Denali Therapeutics is not included in the NASDAQ 100 index

Is Denali Therapeutics in the Dow Jones?

No, Denali Therapeutics is not included in the Dow Jones index

When was Denali Therapeutics's last earnings report?

Denali Therapeutics's most recent earnings report was on Feb 27, 2025

When does Denali Therapeutics report earnings?

The next expected earnings date for Denali Therapeutics is May 7, 2025

Should I buy Denali Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page